Cancer Immunotherapy Market By Technology (Cellular Immunotherapy, Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines and Cytokine Therapy); By End-User (Hospitals, Ambulatory Surgical Centers (ASC’s), Clinics and Others) - Global Industry Demand Analysis & Opportunity Assessment 2017-2027

  • Report ID: 1087
  • Published Date: Feb 07, 2023
  • Report Format: PDF, PPT

Cancer Immunotherapy Market Overview

The cancer immunotherapy market exhibits discernible innovation and is considerably proliferating various cancer immunotherapeutic drugs owing to the rising cases of cancer around the world. With various technological advancements over the years, there has been an increasing number of therapeutics being developed that are more targeted,specific and personalized to the cancer and the patient. As every cancer is different and how it manifests in every patient is unique resulting in specific treatment requirements, there has been an increasing trend in the recent years to develop more therapeutics that can selectively identify the cancer cells and evoke an immune response against them while leaving out the normal cells. This results in minimized side effects that are otherwise seen with conventional therapies such as chemotherapy and radiation therapy, eventually resulting in faster control and recovery with improved quality of life. The global cancer immunotherapy market reached USD 42,584.18 Million in 2017. Moreover, the market is expected to garner USD 86,678.7 Million by the end of 2027 by registering a CAGR of 7.5% during the forecast period 2018-2027.

The global demand for cancer immunotherapy is increasing due to massive growth of healthcare industry across the globe. Further, increasing awareness about early diagnosis and advanced personalized medicine as a part of targeted therapy is one of the key growth drivers for the global cancer immunotherapy market over the forecast period.

Regional Growth Highlights during 2017-2027

The global cancer immunotherapy market is segmented by regions into North America, Latin America, Europe, Asia-Pacific and Middle East and Africa, out of which, the North America is slated to dominate by accounting for a share of around 37.0% by 2027 in the overall cancer immunotherapy market. The growth in the region can be attributed to growing prevalence of various types of cancer. Increasing technological innovations in cancer immunotherapy is also expected to impel the growth of the cancer immunotherapy market in North America where U.S. is the prominent country driving the growth in the region. Further, the region to hold second largest market share in the cancer immunotherapy market is Europe that accounted for around 29% of the total market share in 2017 and is believed to behold its positive growth over the forecast period. Europe Cancer Immunotherapy market is expected to mark 8.6% growth rate in 2027 where Germany is the prominent market driving the growth in the region and is expected to achieve Y-o-Y growth rate of 8.9% in 2027.

Furthermore, China is the major contributor behind the growth of the Asia Pacific cancer immunotherapy market and is expected to achieve Y-o-Y growth rate of 9.1% in 2027.

Cancer Immunotherapy market share

Get more information on this report: Download Sample PDF

Market Segmentation Synopsis

By Technology

Global cancer immunotherapy market is segmented on the basis of technology into cellular immunotherapy, monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines & cytokine therapy. Among these segments, monoclonal antibodies segment accounted for the highest market share of around 65% in 2017 and is further expected to capture the remarkable market share over the forecast period. This is primarily attributed to the technological superiority of this approach due to the high drug specificity towards cancer cells. These drugs are engineered to identify and generate a targeted immune response against the cancer cells based on their cell surface proteins and avoid the normal cells. In addition, immune checkpoint inhibitors segment of the cancer immunotherapy is expected to achieve Y-o-Y growth rate of 8.9% in 2027.    

Cancer Immunotherapy market share by technology

By End-User

The global cancer immunotherapy market is divided by the end user segment into hospitals, ambulatory surgical center (ASC’s), clinics and others, out of which, the hospital segment contributed around 65% of the total market share in 2017 and is expected to witness dominant share during the forecast period i.e. 2018-2027. Further, the hospitals segment is projected to achieve Y-o-Y growth rate of 8.1% in 2027. Apart from this, ambulatory surgical centers is expected to grow significantly with maximum CAGR over the forecast period. This is primarily attributed to increasing number of facilities within the ASC category especially within the US and many of the European countries. There is an increasing number of treatment strategies being developed that do not require overnight stay. The increasing demand for out-patient services such as IL-2 infusion procedures that do not require overnight stay and are resulting in an increasing influx of patients within these facilities. Also, free standing or super-specialty clinics are trying to offer comprehensive therapeutic solutions that usually do not require overnight stay.

Cancer Immunotherapy market by end user

The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Market Drivers & Challenges

Growth Indicators

Immunotherapy is the process that suppresses or enhances the immune system so as to cure the cancer. It operates as complementary treatment to several other forms of treatments such as radio therapy and or chemotherapy. The major reasons behind the growing number of cancer cases around the globe are higher consumption of alcohol, generality of smoking and depletion of the ozone layer. The leading countries with the highest population of cancer patients around the world are United States, China, India, Germany and Russia among others. The global cancer immunotherapy market is thriving on the back of growing rate of cancer patients along with rising awareness and advanced personalized medicines regarding cancer among people.

Additionally, the introduction of numerous healthcare facilities and schemes by governments of various nations regarding cancer immunotherapy are also believed to supplement the global cancer immunotherapy market to grow in near future.


The immunotherapy treatment is limited to developed regions such as North America and Western & Central Europe along with few developing regions such as India, China and Latin America which are believed to witness noticeable growth in upcoming years. Further, the time span and high cost required in the research and development of immunotherapeutic drugs might dampen the growth of the global cancer immunotherapy market.

Top Featured Companies Dominating The Market

Some of the affluent industry leaders in the global cancer immunotherapy market are AstraZeneca, Merck & Co., Novartis, Advaxis Inc., Bristol-Myers Squibb (BMS), Bayer AG, Roche, Eli Lilly and Co., Amgen Inc. and Pfizer Inc.

Regular product launches with new factors incorporated into the products help the companies to create reputation in the market. The companies are entering into numerous strategic partnership and collaboration programs to expand their product offering range and to grow strongly in the market. For instance, recently German drugs company Bayer signed deal with US biotech firm Loxo Oncology in the United States for two new cancer drugs to underline the strength of its pharmaceutical division.


In the News

  • Roche Pharma and India’s third largest drug maker Cipla tied up to promote and distribute tocilizumab (Actemra) and Syndyma, the 2nd brand of Roche’s cancer therapy, bevacizumab (Avastin) in India.
  • Merck has acquired the company Viralytics Limited which is an Australian publicly traded company focused on oncolytic immunotherapy treatments for a range of cancers.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 1087
  • Published Date: Feb 07, 2023
  • Report Format: PDF, PPT

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying